Get started
Author

Adi Al-Nuseirat

Observed names: ADI AL-NUSEIRAT, Adi F. Nuseirat, Al-Nuseirat, Adi
ORCID: 0000-0002-7259-7577
Observed ORCID: 0000-0002-7259-7577
OpenAlex ID: A5037847646
Solid-State Characterization of Fluconazole
2002 · Khouloud A. Alkhamis, Aiman A. Obaidat, et al. · Pharmaceutical Development and Technology · 64
Candida tropicalis —A systematic review to inform the World Health Organization of a fungal priority pathogens list
2024 · Caitlin Keighley, Hannah Yejin Kim, et al. · Medical Mycology · 48
An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
2021 · Sayer Al-Azzam, Nizar Mahmoud Mhaidat, et al. · Antibiotics · 48
PDF
Pharmaceutical regulations in Iraq: from medicine approval to postmarketing
2021 · Ali Azeez Al-Jumaili, Manal Mohammed Younus, et al. · Eastern Mediterranean Health Journal · 47
Fusarium species,Scedosporium species, and Lomentospora prolificans: A systematic review to inform the World Health Organization priority list of fungal pathogens
2024 · Tina Marinelli, Hannah Yejin Kim, et al. · Medical Mycology · 22
PDF
Pharmaceutical policies and regulations of oral antiviral drugs for treatment of hepatitis C in Egypt—case study
2021 · Mahmoud H. Teaima, Adi Al-Nuseirat, et al. · Journal of Pharmaceutical Policy and Practice · 8
Global research funding for traditional, complementary and integrative medicine
2025 · Amie Steel, Kirsten Baker, et al. · Bulletin of the World Health Organization · 5
PDF
Formulation and Characterization of Odt Using Different Co-process Containing Daclatsvir: in Vitro and in Vivo Pharmacokinetics Study on Healthy Volunteers for Hepatitis C Treatment
2022 · DALIA ABOUHUSSEIN, MAHMOUD H. TEAIMA, et al. · International Journal of Applied Pharmaceutics · 1
PDF
Works count: 10
Citation count: 243
H-index: 6
I10-index: 5
Year
Topic
Type